Navigation Links
FDA Approves New Drug to Treat Type I and Type II Diabetes

The Food and Drug Administration (FDA) today approved Symlin, an injectable medicine to control blood sugar for adults with type 1 and type 2 diabetes. Symlin is to be used in addition to insulin therapy in patients who cannot achieve adequate control of their blood sugars on intensive insulin therapy alone.

Symlin will be the only therapy for the treatment of type 1 diabetes other than insulin. Patients with type 2 diabetes already have several other types of oral therapies available.

The safety and efficacy of Symlin were studied in approximately 5000 patients. Overall Symlin therapy was associated, in patients with both types of diabetes, with improvements in the control of blood glucose and with weight loss. So-called "tight" control of blood sugar is desirable in all patients with diabetes in order to reduce risks for long-term adverse consequences of the disease, including blindness, kidney disease, and vascular disease.

Symlin is to be used only in combination with insulin to help lower blood sugar during the 3 hours after meals. Symlin will have a Medication Guide (FDA-approved patient labeling) and a Risk Minimization Action Plan (RiskMAP) due to three areas of concern. First, the principle risk associated with Symlin therapy is hypoglycemia, and this risk is greatest in patients with type 1 diabetes and in patients with gastroparesis (motility problems of the stomach-a long-term complication of diabetes). Second, the potential for medication errors, specifically mixing of Symlin with insulin in the same syringe, which can alter the activity of the insulin, is addressed in the Medication Guide and in physician labeling. Finally, the potential for off-label use in patients where the benefit/risk profile has not been characterized or demonstrated is also a concern and will be monitored by the sponsor.

The Medication Guide informs patients that Symlin should only be used if they are already using their insulin as prescribed, but
'"/>

Source:US FDA


Page: 1 2

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. FDA Approves New Treatment for Chronic Hepatitis B
3. Discovery Could Lead To Novel Approaches In HIV Treatment
4. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Ophthalmologists Use Artificial Silicon Retina Microchip To Treat Vision Loss
7. Effective Cancer Treatments Follow The Clock
8. FDA Clears the Way for Generic Versions of Transdermal Patches to Treat Chronic Pain
9. Potential Drug Target For Treating Cocaine Abuse Found
10. Protein Discovery Could Unlock The Secret To Better TB Treatment
11. Embryonic Stem Cells Treated With Growth Factor Reverse Hemophilia In Mice: UNC Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA Approves New Drug Treat Type and Type Diabetes

(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... de 2015 A 10 a. Conferência ... pela BGI de 22-25 de outubro de 2015, em ... conferência está celebrando seu 10 o. aniversário este ano. ... uma das reuniões mais influentes do mundo no ramo ... entusiastas e prazerosos. A ICG-10 se ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... led to an epidemic of obesity and type-2 diabetes in ... University that are due to be published in the 5 ... of Science and also in the PNAS early online edition ... expands the known taxonomic breadth of metabolic disease and suggests ...
... basis for eventual treatment, neurology researchers have shown that ... that helps keep brain activity in balance. The resulting ... underlying reason for seizures and memory defects experienced by ... , "A traumatic brain injury occurs to someone in ...
... have discovered that autoimmunity can be triggered in the thymus, ... fail to recognize just one of the body's thousands of ... that autoimmunity can start in this cradle of the immune ... emerge, such as the pancreas in the case of type ...
Cached Biology News:Dragonfly's metabolic disease provides clues about human obesity 2Dragonfly's metabolic disease provides clues about human obesity 3Dragonfly's metabolic disease provides clues about human obesity 4Dragonfly's metabolic disease provides clues about human obesity 5How brain injury leads to seizures, memory problems 2Proteins anchor memories in our brain 2Proteins anchor memories in our brain 3
(Date:8/26/2015)...  The Diabetes Research Institute (DRI), a Center ... School of Medicine, announced today that the first ... the first time a novel transplant technique for ... Phase I/II study builds upon decades of progress ... first step toward the development of the DRI ...
(Date:8/26/2015)... Aug. 26, 2015 China Cord Blood Corporation ... leading provider of cord blood collection, laboratory ... services, today announced that the Company has been informed ... entity wholly owned by Mr. Yuen Kam, chairman of ... the outstanding shares (the "Shares") of  Excellent China Healthcare ...
(Date:8/26/2015)... ... August 26, 2015 , ... The 2015 Epigenomics & Metabolomics ... cell technology start-up company Asymmetrex to share the first report on progress ... new biomarker for counting adult tissue stem cells. , With a name like “H2A.Z ...
(Date:8/25/2015)... -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced ... company as Chief Operating Officer. Winham, who brings more than ... will report directly to HLI,s CEO, J. Craig Venter ... COO, Winham will be responsible for managing all HLI sequencing, ... operations. HLI currently has three locations in San ...
Breaking Biology Technology:Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 2Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 3Asymmetrex Reports Positive Indicators for Crowdsourcing Campaign to Evaluate New Biomarker for Counting Adult Tissue Stem Cells for the First Time 4Human Longevity, Inc. Hires Life Sciences Leader, Mark Winham, as Chief Operating Officer 2
... ROCHESTER, N.Y., March 24 China,s State ... of the pioneering Lucid VivaScope(R),reflective confocal microscope ... Jay,Eastman, CEO of Lucid, a Rochester, New ... providing improved care for dermatology,patients., Lucid,s ...
... CRY ),a biomaterials, medical device and tissue ... SG pulmonary human heart,valve since the product was ... February. The procedure was performed on a patient ... The CryoValve SG is processed with,the Company,s proprietary ...
... SANTA CLARA, Calif., March 24 Finesse Solutions, ... life sciences process,applications, announces the release of TruFluor(TM), ... Interphex in Philadelphia on March,26, 2008., The ... solution consisting of a disposable sheath, an optical ...
Cached Biology Technology:Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 2Lucid's VivaScope(R) Reflective Confocal Microscope Approved for Sale in China 3CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 2CryoLife Announces Implant of First FDA-Cleared SynerGraft(R) Processed Human Pulmonary Heart Valve 3Finesse Introduces TruFluor(TM) DO, a Single-Use Optical Dissolved Oxygen Sensor and Transmitter 2
p27 rabbit polyclonal antibody...
... Rabbit polyclonal to Ki67 - Proliferation ... prototypic cell cycle related nuclear protein, expressed ... the active cell cycle (G1, S, G2 ... resting (G0) cells. Ki67 antibodies are useful ...
UBC13 Antibody...
Request Info...
Biology Products: